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Abstract
Introduction: Gene expression patterns characterizing clinically-relevant molecular subgroups of glioblastoma are difficult
to reproduce. We suspect a combination of biological and analytic factors confounds interpretation of glioblastoma
expression data. We seek to clarify the nature and relative contributions of these factors, to focus additional investigations,
and to improve the accuracy and consistency of translational glioblastoma analyses.
Methods: We analyzed gene expression and clinical data for 340 glioblastomas in The Cancer Genome Atlas (TCGA). We
developed a logic model to analyze potential sources of biological, technical, and analytic variability and used standard
linear classifiers and linear dimensional reduction algorithms to investigate the nature and relative contributions of each
factor.
Results: Commonly-described sources of classification error, including individual sample characteristics, batch effects, and
analytic and technical noise make measurable but proportionally minor contributions to inconsistent molecular
classification. Our analysis suggests that three, previously underappreciated factors may account for a larger fraction of
classification errors: inherent non-linear/non-orthogonal relationships among the genes used in conjunction with
classification algorithms that assume linearity; skewed data distributions assumed to be Gaussian; and biologic variability
(noise) among tumors, of which we propose three types.
Conclusions: Our analysis of the TCGA data demonstrates a contributory role for technical factors in molecular classification
inconsistencies in glioblastoma but also suggests that biological variability, abnormal data distribution, and non-linear
relationships among genes may be responsible for a proportionally larger component of classification error. These findings
may have important implications for both glioblastoma research and for translational application of other large-volume
biological databases.
Citation: Marko NF, Quackenbush J, Weil RJ (2011) Why Is There a Lack of Consensus on Molecular Subgroups of Glioblastoma? Understanding the Nature of
Biological and Statistical Variability in Glioblastoma Expression Data. PLoS ONE 6(7): e20826. doi:10.1371/journal.pone.0020826
Editor: Vladimir Brusic, Dana-Farber Cancer Institute, United States of America
Received February 25, 2011; Accepted May 9, 2011; Published July 28, 2011
Copyright:  2011 Marko et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors wish to thank the Melvin Burkhardt chair in neurosurgical oncology and the Karen Colina Wilson research endowment within the Brain
Tumor and Neuro-oncology Center at the Cleveland Clinic Foundation for partial support and funding. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript. There are no current external funding sources for this study.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: markon@ccf.org (NFM); weilr@ccf.org (RJW)
Introduction
Glioblastoma (GBM) is the most common primary malignant
brain tumor in adults, and optimal surgical and medical
management of this disease result in a mean survival of only
12–14 months [1,2,3,4,5]. Intense efforts over the past several
decades to advance GBM therapy have resulted in only modest
improvements in survival for patients with theses tumors, and the
current management strategy remains attempted gross total
surgical resection followed by radiation and adjuvant chemother-
apy [6]. While the prognosis remains poor for most GBM patients,
a small subset (10–25%) survive two or more years from the time
of initial diagnosis [5,6,7,8]. This variable response to standardized
management suggests the existence of two or more major clinical
subgroups of GBM patients with unique survival and response-to-
therapy phenotypes. These subgroups are not readily identified by
the current, histological grading and World Health Organization
(WHO) classification schemes, prompting a search for alternate
strategies for glioma classification.
The recent development of high-throughput molecular tech-
niques for comprehensive characterization of tumor genomes and
transcriptomes has been embraced by the translational neuro-
oncology community and has been applied to the challenge of
molecular GBM subclassification. Numerous investigators have
reported successful identification of gene expression patterns
characteristic of distinct tumor genomic profiles associated with
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e20826unique clinical phenotypes [8,9,10,11,12,13,14,15]. These results
suggest that molecular analyses may improve prognostication in
patients with GBMs and, more importantly, may identify subsets
of GBM patients prospectively with distinct survival or response-
to-therapy phenotypes.
Initial optimism that molecular classification tools represent a
major breakthrough in GBM management has, more recently,
been tempered by the lack of consistency and reproducibility of
genomic signatures with putative associations to survival pheno-
types. While multiple groups have reported the ability to predict
patient survival accurately based upon specific gene expression
signatures [8,12,13,15], there is little overlap between the specific
signatures reported by each group. Although it may be appealing
to conclude that differences in the complex, multistep algorithms
for gene selection can explain the variability among the specific
genes comprising each reported molecular ‘‘survival fingerprint,’’
it is difficult to verify that analytic (rather than biologic or
technical) differences are the principal determinants of this
variability. Moreover, while hypothesis generation abounds
regarding the potential biological significance of the genes in each
profile, evidence supporting such hypotheses has heretofore been
lacking. This problem is compounded by persistent uncertainty
regarding the relative strengths and weaknesses of individual
analytic models to capture phenotypically-relevant biology, and
attempts to optimize these models is hindered by our incomplete
understanding of cancer systems biology. Together, these
observations can cast suspicion upon the biologic significance of
the GBM expression signatures described by each group, and,
consequently, upon the ultimate potential for clinical utility of this
approach to molecular subclassification. While most translational
neuro-oncologists believe that the future of GBM research lies in a
better understanding of the molecular biology of these tumors, few
agree on the specific genes of interest, the optimal approach to
using genomic data to generate knowledge regarding the systems
biology of these tumors, or the ideal strategies to apply this
information to the classification and clinical management of GBM
patients.
One step to address the challenges associated with analyzing
and interpreting this data has been the development of a central
repository of genomic and epigenetic data for GBMs. The Cancer
Genome Atlas (TCGA) project [16] was designed as such a data
repository, and GBM was the first tumor type to be cataloged and
shared through the TCGA infrastructure [9,14]. Public availability
of this data increases both the number of investigators searching
for novel genome/phenotype correlations in GBMs and the scope
of biological hypotheses generated regarding such correlations;
however, the accuracy, reproducibility, and utility of these
investigations will remain uncertain until the factors responsible
for the observed inconsistencies in GBM molecular classification
can be identified, modeled, and prospectively addressed.
Comprehensive investigation of the potential sources of
molecular classification errors in GBM requires questioning the
fundamental assumptions regarding both the nature of the
expression data itself and the analytic strategies used for its
analysis. We hypothesize that a combination of biological and
mathematical factors confound interpretation of this data, and we
have undertaken a comprehensive investigation into the nature
and relative contributions of these factors to inconsistencies in
molecular classification of GBMs. To investigate our hypothesis,
we constructed a logic model (Figure 1) to organize the major
potential sources of error associated with current analyses of GBM
expression data.
Logic models are narrative or graphical depictions of processes
that communicate the underlying assumptions upon which an
activity is expected to lead to a specific result. Such a model
describes the logical linkages between elements of a process as a
linear sequence of inputs, activities (in our case analytical steps),
outputs, and outcomes [17,18]. Once a program has been
described in terms of a logic model, critical measures of
performance can be identified. Having constructed our logic
model, we then used as the basis for asking five (5) questions
regarding the classification variability associated with the possible
factors introducing error into any analysis of genomic data. Next,
using publically-available (TCGA) GBM expression data [16], we
designed and conducted eleven (11) mathematical analyses
intended to address these five questions. We believe that this
approach, which represents the first application of this type of
analytic model to a large, publically-available gene expression
database, provides a comprehensive framework for investigating
and understanding the type, nature, and complex interrelationship
among potential sources of error that may confound current
strategies for molecular analysis and classification of GBMs.
Results
Eleven analyses were conducted to test the logic model outlined
in Figure 1. The design and results of these analyses are described
below, and their positions in the logic model are indicated
numerically on the figure. For reference purposes, an unannotated
version of this figure has been included in the supplemental
material (Figure S1).
Multiple Tumor Stratification (#1)
Unsupervised classification using hierarchical clustering (HCL)
[19] and principal components analysis (PCA) [20,21] were
performed on an Robust Multichip Analysis (RMA) –normalized
[22,23,24] dataset containing 364 samples (340 GBM, 20 renal
cell carcinoma [RCC], 4 hepatocellular carcinoma [HCC]). Both
methods yielded excellent separation of the three, distinct tumor
types based upon gene expression profiles (Figure 2). Next,
minimally-supervised clustering using k-means clustering (KMS)
[25] was performed. The value of k was set as 2 for this analysis,
testing the ability to separate the GBMs from the aggregate group
of RCC+HCC (i.e. GBM versus non-GBM) in a retrospective
analysis. The analysis was repeated 100 times to minimize random
classification effects that may be attributable to disproportionate
allocation of tumor types in the population. This method achieved
separation of the two groups with 99.6% accuracy (2/340
misclassifications, data not shown). Finally, the k-nearest neighbor
clustering algorithm (KNNC) [26] was used to test the accuracy of
prospective classification of novel samples as either GBM or non-
GBM (k=2) based upon expression profile. The KNNC was first
trained with a randomly-selected set of 170 GBMs and 13 non-
GBMs and was then tested using a novel set of 170 GBMs and 13
non-GBMs. This classifier achieved a 98.9% accuracy rate (2/170
misclassifications, data not shown). Together these results
demonstrate the presence of a unique gene expression signature
present within the TCGA data that is characteristic of GBMs and
that is distinct from the molecular signatures of other malignan-
cies.
Unsupervised Classification and Clinical Parameters (#2)
Unsupervised classification using hierarchical clustering with
bootstrapping support (HCS), KMS, and PCA was performed on
the dataset containing 340 GBMs normalized to controls to
investigate whether unbiased clustering algorithms would separate
the population of GBMs into genomic subsets with corresponding,
clinically-relevant phenotypes. Eight versions of each analysis were
Variability in Molecular Classification of GBM
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eight clinical phenotypes with known or potential clinical
significance recorded in the TCGA dataset. The results of the
complete PCA analysis are presented in Figure 3, and represen-
tative results from the HCS and KMS analyses are given in
Figure 4. These analyses demonstrate that three different unbiased
class discrimination algorithms fail to segregate the GBM
population into genomic subgroups correlated with any of the
eight, clinically-relevant phenotypes for which clinical data is
available.
Eigenvalue Analysis (#3)
To study the extent to which the principal components (PC)
describe the variability in the GBM population, we examined the
eigenvalues resulting from the PCA matrix decomposition of the
dataset containing 340 GBMs normalized to controls. Eigenvalues
for each PC were computed both as a raw value and as a percent
of the cumulative total eignevalue. The eigenvalue plot, as well as
the individual eigenvalues and the eigenvalue percents associated
with each of the first 20 PCs, are presented in Figure 5. This
analysis demonstrates that the first three principal components,
which serve as the basis for class discrimination represented by the
3-D PCA plot, account for only 29.6% of the total molecular
variability of the GBMs. This suggests that this classification model
does not capture or represent 70.4% of the genomic variability in
this dataset. Moreover, it indicates that the most variable genes in
this dataset, which theoretically contribute significantly to the first
three PCs, may not have direct correlations with clinically-relevant
phenotypes.
Biological Analysis of the Outlier Group (#4)
HCS and PCA of the 340 GBMs (normalized to controls)
demonstrated a cluster of 14 tumor ‘‘outliers’’ that consistently
segregated from the remainder of the group in multiple analyses
(Figure 6). We hypothesized that if there was a biological basis to
this segregation, then more genes should be differentially-
expressed between the outlier cluster and the remainder of the
GBM population than would be expected by random chance.
More importantly, functional annotation of the genes that are
differentially expressed between the two groups should reveal
Figure 1. Logic Model for Analyzing Variability in the TCGA GBM Dataset. Annotated logic model, as applied in this investigation to the
TCGA GBM data. The five fundamental questions forming the branch points of the logic model (see Discussion) are indicated in italics, and the
answers to these questions are presented in red. Numbers (brown) corresponding to analyses 1–11 (see Results) are indicated at the locations where
their results provide evidence. Analyses performed as a part of this investigation are indicated in blue, while supporting evidence from the literature
is in green. Future directions for research are indicated in purple and are indicated below the corresponding branch of the model.
doi:10.1371/journal.pone.0020826.g001
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discrete GBM phenotypes. This analysis is qualitative in nature
and limited in its power to draw definitive conclusions, but it
represents one approach to investigate the hypothesis that valid,
biological differences are present within the dataset and are
contributing to the unsupervised tumor stratification.
The significance analysis for microarrays (SAM) [27,28]
algorithm with false discovery rate (FDR)=0 was used to identify
2,501 over-expressed genes (Table S1A) and 2,704 under-
expressed genes (Table S1B) in the outlier group relative to the
remainder of the GBM population, more than would be expected
by chance alone [2,501+2,704=5,205 genes identified by SAM vs.
172 (p=0.01) or 857 (p=0.05) that would be differentially
regulated by pure chance]. EASE [29] overrepresentation analysis
of the structural and functional annotations of these genes,
including annotations from the Gene Ontology [30,31] project,
the Kyoto Encyclopedia of Genes and Genomes [32,33], and
GenMAPP [34,35], demonstrated statistically-significant (EASE
score ,0.05) overrepresentation of 473 categories, many of which
have plausible roles in differential tumor phenotypes (Tables S1C
and S1D). Comparison of this gene list and annotation profile with
a profile that our group previously identified as differentially-
expressed between GBM survival phenotypes [8] demonstrated
overlap in 8 (15%) genes and 6 (46%) categorical annotations
(Table S1E). Together, these results provide qualitative evidence
to suggest that genomic differences with potential phenotypic
significance do exist among the TCGA GBM data and that at least
some of this biological information influences the results of the
clustering algorithms.
Expression Data Distribution Analysis (#5)
One assumption common to most linear classifiers used in
microarray analysis is that the values of the variables upon which
classification is based conform to a Gaussian distribution [21,36].
To test this assumption, we examined the distributions associated
with the RMA normalized, Log2 (tumor/normal) data. We studied
the distribution characteristics of the variables (gene expression
values) in the dataset for the complete expression matrix (17,172
Figure 3. Unsupervised Classification (PCA) Colored by Clinical Phenotypes. GBMs do not segregate on PCA along any of 8 clinically-
relevant parameters recorded in the TCGA database, which suggests that genomic signatures associated with these phenotypic differences are not
identified accurately by this unsupervised, linear data reduction algorithm. A: Survival (Red=top 20
th percentile; Blue=bottom 20
th percentile;
Yellow=intermediate percentiles). B: Time to Progression (Red=top 20
th percentile; Blue=bottom 20
th percentile; Yellow=intermediate percentiles).
C: Time to Recurrence (Red=top 20
th percentile; Blue=bottom 20
th percentile; Yellow=intermediate percentiles). D: Karnofsky Performance Score
(KPS) at diagnosis (Red=100; Yellow=80–90; Blue=70 or less). E: Sex (Blue=male, Pink=female). F: Histologic Evidence of both Endothelial
Proliferation and Necrosis (If yes, coded Green; if no, coded Pink). G: Adjuvant chemotherapy administered (Green=yes, Pink=no). H: Adjuvant
radiotherapy administered (Green=yes, Pink=no). Note1: adjuvant therapy categories are not themselves phenotypic characteristics, but the need
for these therapies may be a surrogate marker for underlying tumor biology and they are therefore included in this analysis. Note 2: for all images,
spheres colored gray or brown=data not available.
doi:10.1371/journal.pone.0020826.g003
Figure 2. Multiple Tumor Stratification. PCA successfully separates
glioblastoma (GBM, Blue) from renal cell carcinoma (RCC, green) and
hepatocellular carcinoma (HCC, red) based upon expression profile.
doi:10.1371/journal.pone.0020826.g002
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gene and per-sample basis. We characterized the distribution by
computing standard descriptive statisticsas well as skew and kurtosis
measurements (and descriptive statistics for each of these measure-
ments). The results of this analysis are summarized in Table 1.
The distribution analysis demonstrates that the TCGA GBM
data deviates from a pure Gaussian distribution both in the overall
expression matrix (Figure 7) and in the per-gene (Figure 8) and
per-sample (not shown) analyses. Examination of the RMA-
normalized, log2(ratio) data reveals that the complete expression
matrix is centered around a mean and median of 0.03 with a
standard deviation of 0.92, suggesting a normal (standard
Gaussian) distribution. However, the skew of this distribution is
20.21, an effect that is easily overlooked on visual inspection
(Figure 7A). While this value may not initially appear to be of
significant magnitude, the statistical significance of the degree of
skew must be considered in the context of the number of variables
(n) associated with the distribution. A test statistic, reflecting the
number of standard errors of skew (SES) [37] away from zero, can
be computed from equation 1:
test statistic~
skewness
SES
where SES~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
6 n ðÞ (n{1)
n{2 ðÞ nz1 ðÞ (nz3)
s
This equation essentially performs a two-tailed test of skew?0,
where a test statistic value of 62 corresponds to p=0.05. Using
n=5,838,480 (the total number of values comprising the expression
matrix), SES=0.001 and the test statistic=2207.2, indicating that
the distribution has a statistically-significant degree of skew.
Similarly, the kurtosis of the distribution is calculated at 6.45
(excess kurtosis=3.45). The statistical significance of the magni-
tude of the kurtosis must also be considered in the context of the
number of variables (n) associated with the distribution, and a test
statistic reflecting the number of standard errors of kurtosis (SEK)
[37] away from zero, can be computed from
equation 2:
test statistic~
kurtosis{3
SEK
where SEK~2(SES)
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n2{1
n{3 ðÞ nz5 ðÞ
s
For n=5,838,480, SEK=0.002 and the test statistic=1701.6,
indicating that the distribution has a highly statistically-significant
degree of leptokurtosis (Figure 7B).
Figure 4. Unsupervised Classification (HCS, KMS) Colored by Survival Phenotype. The topmost color gradient bar displays the scale along
which the Log2 (tumor/control) values for each gene are colorized in the dendrogram. The color bars immediately above the dendrogram branches
indicate the survival phenotype group to which each sample belongs: Red=top 20
th percentile of survival time; Blue=bottom 20
th percentile;
Yellow=intermediate percentiles, Black=survival not recorded. A: Hierarchical clustering with support (bootstrapping with 20 iterations)
demonstrates no separation by survival phenotype. Support values for each node of the dendrogram also reveal significant inconsistency in
clustering, suggesting underlying noise (black=100% support, gray=90–99%, blue=80–89%, green=70–79%, yellow=50–69%, pink/red ,50%).
Only the topmost portion of the full heatmap is depicted in this figure. B: Clusters resulting from k-means support (k=2, 10 iterations), again showing
no segregation by survival phenotype.
doi:10.1371/journal.pone.0020826.g004
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statistics are computed for each gene (a per-gene analysis, where
n=340), the mean skew is 0.64 (mean test statistic=4.84) and the
mean kurtosis is 3.07 (mean excess kurtosis 0.07, mean test
statistic=0.27). A similar analysis done on a per-sample basis
(n=17,172) demonstrates a mean skew of 20.18 (mean test
statistic=29.64) and a mean kurtosis of 5.82 (mean excess kurtosis
2.82, mean test statistic=75.34), suggesting significant deviations
from a pure Gaussian distribution in both analyses. Examples of
the diversity of skew and kurtosis of gene distributions are given in
Figure 8. While the classification implications of these deviations
from the Gaussian distribution require further investigation
Figure 6. Outlier Group. A group of 14 outliers (red box) is consistently identified with various unsupervised clustering algorithms, including
hierarchical clustering (A) and PCA (B). Note: a reproduction of Figure 3G has been used here and is colorized in an identical fashion.
doi:10.1371/journal.pone.0020826.g006
Figure 5. Eigenvalue Decomposition Analysis of PCA. Eigenvalues for all principal components are plotted, and numeric values for the
eigenvalue percentages and cumulative percentages of the first 1–3 principal components are given. See text for discussion.
doi:10.1371/journal.pone.0020826.g005
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data violates the Gaussian assumption that is a fundamental
precondition of most linear classifiers.
Unsupervised Classification and Technical Parameters
(#6)
Unsupervised classification using PCA was performed on the
dataset containing 340 GBMs (normalized to controls) to
investigate whether unbiased clustering algorithms would separate
the population of GBMs into subsets corresponding to technical
differences related to the samples or to their processing. Eight
versions of the analysis were performed, with samples colorized
according to one of eight technical parameters that could
introduce classification error. The results of this analysis
(Figure 9) demonstrate that these eight technical parameters do
not appear to be major contributors to the first three principal
components and are therefore unlikely to be primary contributors
to classification errors or inconsistencies.
Platform Noise and Chip Quality Analysis (#7)
Multiple technical variables associated with sample preparation,
hybridization efficiency, physical array quality, and image
acquisition can contribute to technical noise and subsequently to
classification error. These effects have been studied extensively
[39,40,41,42,43,44,45,46,47,48], and numerous modeling and
optimization strategies have been suggested to estimate and to
minimize technical noise [40,49,50,51,52,53]. Implementation
and optimization of such modeling is beyond the scope of this
investigation, but semi-quantitative estimation of the magnitude
and effects of technical noise are useful to illustrate their relative
importance for this dataset.
For each gene in each array, the MAS5 algorithm [54]
calculates a discrimination score (Ri) based upon the relative signal
levels measured for the perfect match (PM) and mismatch (MM)
cells for each probeset. A one-sided Wilcoxon’s Signed Rank Test
is used to calculate a p-value associated with Ri. Comparison of the
p-value with user-defined threshold values (a1 and a2) serves as the
basis for the algorithm’s present/absence call, and the p-value
itself can be conceptualized as a measure of confidence that the
measured signal is the result of valid hybridization rather than
background noise. Qualitative assessment of the extent of the noise
in the TCGA dataset was performed by calculating the percentage
Table 1. Descriptive Statistics for the TCGA GBM Distribution.
T RMA Normalized, Log2 (Tumor/Normal)
Standard
Gaussian
(normal)
By Gene By Sample Overall
Distribution
Mean 0.03 0.03 0.03 0.00
Median 0.00 0.04 0.03 0.00
SD 0.45 0.91 0.92 1.00
Skew 20.21 0.00
Mean 0.64 20.18
Median 0.50 20.20
SD 1.14 0.33
Min 27.57 21.00
Max 14.13 1.06
Kurtosis 6.45 3.00
Mean 3.07 5.82
Median 0.86 5.88
SD 9.97 1.14
Min 21.60 2.69
Max 236.58 9.35
Note that both the mean and median are approximately equal to zero and the
standard deviation is approximately equal to 1. Measurements of skew and
kurtosis deviate from those expected for a Gaussian distribution, and test
statistics indicate that these deviations are statistically significant (test statistic
.2 approximately corresponds to p,0.05, see text). These results are depicted
graphically in Figure 7.
doi:10.1371/journal.pone.0020826.t001
Figure 7. Distribution of the Complete Gene Expression Matrix for the TCGA GBM Data. A: TCGA GBM expression matrix histogram. The
zero position on the abscissa is indicated with a red meridian. Careful inspection (particularly at the apex) reveals the negative skew. B: Overlay of the
TCGA GBM distribution and the standard Gaussian (normal) distribution. This representation, in particular, demonstrates the leptokurtosis of the
TCGA GBM data distribution. Scales of the ordinates have been adjusted to facilitate distribution overlay.
doi:10.1371/journal.pone.0020826.g007
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p.0.01 (51.50%). This analysis suggests that approximately 40–
50% of the individual expression measurements in the matrix are
not significantly different from background. We performed similar
analysis on smaller sets of previously-published expression data for
GBMs (n=20) [8] and for low-grade gliomas (n=23) [55] and
found similar percentages for each dataset (45.98%/57.35% and
50.43%/64.16%, respectively). Similarly, we calculated the
percentages for genes called present, absent, and marginal by
the MAS5 algorithm (with a1=0.05, a2=0.065, t=0.015) for the
TCGA dataset and for the two comparison datasets and again
found comparable values in each category (Table 2).
Next, we used the p-value associated with Ri as the basis of a
semi-quantitative analysis examining the effects of technical noise
on clustering results. We recognize that this is not a comprehensive
marker of all possible sources of technical noise, but it is a useful
index of one dimension of this noise and has been used as a
surrogate marker for array noise in other investigations [49]. We
computed the mean of the p-value (pm) for each gene across the set
of 340 arrays and subsequently filtered out genes for which
pm.0.05 from the RMA-normalized dataset used in our other
analyses. We then performed PCA on this filtered dataset and
found no qualitative improvement in clustering into survival
phenotypes (data not shown). The sum of the first three eigenvalue
percentages from this analysis was slightly better than that of the
unfiltered data (34.4% vs 29.6%). Together, the results of these
analyses suggest that technical noise is present within the TCGA
dataset but that it does not appear to be the major factor
confounding clustering into clinically-relevant phenotypes.
Chip quality was also performed to identify areas of chips with
inhomogeneous signal characteristics. This can be attributable to
physical errors on the chips, fluidics errors, regional binding
inconsistencies, or other regional effects. We first examined the
virtual chip images created using the RMA Express [22] software
package’s QA tools. These pseudoimages are derived from the
RMA algorithm’s residual PLM values and are capable of
highlighting areas of inhomogeneous signal on the array chips.
We considered chips to have significant regional error if
inhomogeneities were identified on at least part of 5 or more of
the 49 subgrids (,10%) of the array chip (Figure 10). A total of 24
chips (7.1%) with such regional errors were then excluded from
subsequent clustering analysis. PCA clustering demonstrated no
apparent improvement in ability to segregate survival phenotypes
after exclusion of these chips (data not shown) and no significant
improvement in the sum of the eigenvalue percentages associated
with the first three principal components (27.6% vs 29.6%). We
Figure 8. Distributions of Three Sample Genes from the TCGA GBM data. The expression distributions across all 340 GBM samples of three,
representative genes with approximately equal means, medians, and standard deviations are plotted. Note that, for each sample, the mean and
median are nearly equal and the standard deviation is approximately equal to 1. These descriptive statistics suggest a Gaussian distribution. However,
the three distributions are significantly unequal, a finding only reflected in the measurements of skew. Mild kurtotic effects can also be observed. Test
statistics for skew and kurtosis are calculated as described in the text. (Note: The negatively skewed sample gene is TCEAL2]211276_at], the positively
skewed sample gene is CENTA1 [90265_at], and the unskewed gene is CYFIP2 [21578_s_at].).
doi:10.1371/journal.pone.0020826.g008
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quality, including either evidence of regional errors in 3 of 49
(,6%) subgrids or other patterns potentially suggestive of
nonbiological inconsistency (see Figure 10). This resulted in
exclusion of 108 (31.8%) arrays but did not improve qualitative
classification (data not shown) or cumulative eigenvalue percent-
ages (27.8% vs. 29.6%) in subsequent PCA analysis. Both analyses,
however, did result in a change in morphology of the PCA plot
(relative to the plot of the unfiltered data, data not shown), the
significance of which requires further investigation. Together these
analyses suggest that platform noise and chip quality are present in
the TCGA GBM dataset but may not be the primary contributors
to inaccuracies in sample classification.
Data Filtering (#8)
Two potential sources of statistical noise that may impede
classification are genes with either relatively static expression levels
throughout the data set or genes for which expression values are
absent in a significant portion of the expression matrix. We
performed a series of data filtering analyses designed to investigate
the effects of these variables, in isolation and in combination, on
unsupervised classification into survival groups. We first performed
PCA using the baseline data set of 340 GBMs (relative to controls)
and then repeated this analysis using progressively stringent
variance and present/absent data filters on the normalized dataset.
These filters removed the least variable 50% or 80% of genes
(variance filter) or limited inclusion of genes to those with
measurable signal present in .50%, .80%, or in 100% of
samples (percent present filter). Data filtering trials were
performed with individual filters or with combinations of the
variance and percent present filter in place at various individual
thresholds. PCA was performed on each of the filtered datasets,
and the ensuing classifications were evaluated qualitatively by
examining the plots of the first three principal components
(colorized by survival) and semi-quantitatively by analyzing the
eigenvalue percentages associated with each of the first three
principal components in each of the trials (Figure 11). The results
of the semi-quantitative analysis show a trend toward increasing
eigenvalue percentage as progressively more stringent criteria are
applied, suggesting that statistically ‘‘noisy’’ genes do contribute, to
some degree, to the variability represented by the first three
principal components. The qualitative analysis demonstrated that,
while filtering changed the overall morphology and orientation of
the sample cloud in 3-dimensional, PCA space, the observed
reduction in variability did not improve the accuracy of
stratification into clinically-relevant subgroups. Overall, these
results suggest that technical variability introduced by genes with
relatively homogeneous or absent expression are a source of
Table 2. Analysis of MAS5 p-values as Markers of Background
Noise.
TCGA
GBMs
Comparison
GBMs
Comparison Low
Grade Gliomas
Call=Present 58.2% 44.5% 49.6%
Call=Absent 40.6% 54.0% 48.6%
Call=Marginal 1.2% 1.5% 1.9%
p.0.05 41.8% 46.0% 50.4%
p.0.01 51.5% 57.4% 64.2%
P-values were computed by the Affymetrix MAS5 algorithm using a one-sided
Wilcoxon Signed Rank Test. ‘‘Call’’ refers to the Affymetrix Present/Absent call.
Comparison GBMs were initially reported in Marko et al., 2008 [8], and
comparison low-grade gliomas were reported in Marko et al. 2009 [55].
doi:10.1371/journal.pone.0020826.t002
Figure 9. Unsupervised Classification (PCA) Colored by Technical Phenotypes. GBMs do not segregate on PCA along any of 8 technical
parameters recorded in the TCGA database. This suggests that these factors are not primary contributors to erroneous misclassification. A: Tissue
Sample Size (Red=top 20
th percentile; Blue=bottom 20
th percentile; Yellow=intermediate percentiles). B: Clinical Center of Origin (By TCGA ID
number: Red=02, Green=06, Blue=08, Yellow=12, Purple=Other). C: RNA Concentration (Red=top 20
th percentile; Blue=bottom 20
th percentile;
Yellow=intermediate percentiles). D: Optical Density 260/280 nm (Red=top 20
th percentile; Blue=bottom 20
th percentile; Yellow=intermediate
percentiles). E: Ribosomal 28S/18S (Red=top 20
th percentile; Blue=bottom 20
th percentile; Yellow=intermediate percentiles). F: RNA Index Number
(Red=top 20
th percentile; Blue=bottom 20
th percentile; Yellow=intermediate percentiles). G: .50% Tumor Cells in Sample (Green=yes, Pink=no).
H: Prior Treatment (Green=yes, Pink=no). Note: in all figures, gray=data not available.
doi:10.1371/journal.pone.0020826.g009
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factors impeding accurate phenotypic classification of GBMs in
the TCGA data set.
Batch Effects Analysis (#9)
The TCGA GBM data set includes 340 samples derived
collected from patients treated at multiple clinical centers and
processed at one of several sample preparation laboratories.
Combining the data from such samples may introduce batch
effects into the concatenated data set. This phenomenon has been
well described by array statisticians [56] but is sometimes
overlooked by clinician-scientists using large, public datasets for
hypothesis generation and testing. We analyzed the potential
contribution of batch effects in the TCGA GBM data to tumor
misclassification using both a ‘‘bottom-up’’ and a ‘‘top-down’’
approach. For the ‘‘bottom-up’’ analysis, we first prepared several
data subsets in which samples were matched for approximate
tissue size, OD260/280, 28S/18S, and RNA integrity number
(RIN). We held constant either clinical center of origin or TCGA
batch number while varying the other parameter. PCA was
performed on the data subsets, and samples were colorized by the
variable parameter. This approach facilitates qualitative explora-
tion of the independent batch effects associated with either clinical
center of origin or TCGA batch number, although it is limited by
the scope of the technical data reported in TCGA as to the
number of technical parameters that can be matched or
controlled. The results of these analyses demonstrate no gross
clustering trends associated with either center of origin or with
TCGA batch, although caution must be used in interpreting this
data because the qualitative nature of the analysis limits the extent
to which batch effects can be studied.
Recognizing the limitations of the ‘‘bottom-up’’ analysis, we also
performed qualitative and semi-quantitative analysis of batch
effects using a ‘‘top-down’’ approach. We assumed the presence of
some batch effects associated with clinical center of origin and
TCGA batch, attempted to correct empirically for such errors, and
compared the PCA plots and the eigenvalue data before and after
correction to obtain a post hoc estimate of the classification impact
of batch effects. We implemented this analysis by first performing
baseline PCA analysis (colorized by survival) with eigenvalue
decomposition on the complete set of 340 GBMs. Next, we applied
the ComBAT algorithm [57], a tool that uses a Bayesian approach
based upon empirical and parametric priors to reduce batch
effects. We ran ComBAT using TCGA batch as the primary effect
and clinical center of origin as the covariate. We repeated the PCA
and eigenvalue analyses on the ‘‘corrected’’ dataset. The results of
this analysis suggest that some center-of-origin and TCGA-batch-
number batch effects are present in the concatenated data set. The
result of correction for these effects can be observed qualitatively
by comparing the pre- and post-combat PCA plots (Figure 12).
The latter appears to demonstrate a reduction in correlation
between the first two principal components, suggesting that batch
effects may contribute to the identity and subsequent stratification
of samples along these two components in some underlying and
correlated fashion. Notwithstanding, the application of ComBAT
does not result in qualitative improvement in phenotypically-
significant (survival) clustering, suggesting that batch effects are not
the primary contributor to classification error. This finding is
verified by semi-quantitative analysis using the eignevalue data,
which shows only a slight improvement in the sum of the first three
eigenvalue percents (31.2% vs 29.6%).
Progressive Tumor Population Size Analysis (#10)
Although increasing the number of samples in a microarray
experiment may increase classification power in some instances,
this presupposes that the signal-to-noise ratio of the samples is
higher than those of the base set. If the opposite is true or if the
SNRs are approximately equal, then increasing population size
may either disproportionately introduce noise that could impede
classification or may have little to no added effect, respectively. To
study the possibility of this effect in the TCGA GBM data, we used
a random number generator to randomly divide the RMA-
normalized, 340 tumor dataset into 6 subgroups of approximately
equal size (n=5764, n=5662). We then progressively combined
the subsets, creating five sub-populations of 114, 171, 228, 284,
and 340 samples. Qualitative PCA and eigenvalue analysis were
performed on each of the six subsets and on the five sub-
populations. The results of these analyses demonstrate approxi-
mately stable magnitude of the eigenvalue percentages associated
with each of the first three principal components in all subsets and
concatenated sub-populations, and qualitative analysis of the PCA
data does not demonstrate appreciable improvement (or decline)
in phenotypic classification accuracy as the population size
increases (Figure 13). These findings suggest that there is little
Figure 10. Assessment of Array Chip Quality. Pseudo-chip images
created from the RMA probe-level modeling (PLM) residual values were
used to screen chips for quality. The presence of either positive (red) or
negative (blue) residuals indicates some degree of deviation from the
ideal (zero residual) value and therefore suggests some degree of error
in the measurement. Technical problems may result in nonrandom
regions of unusually large residuals. Depicted are examples of chips
considered to be of good (A), intermediate (B), or poor (C) quality in our
analysis.
doi:10.1371/journal.pone.0020826.g010
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accuracy for the TCGA GBM expression data.
Two-Dimensional Analysis of Principal Components
(#11)
A necessary condition for successful class discrimination by
linear classifiers or data reduction algorithms is that the
relationships between the variables used for classification must
be linear [36]. Additionally, many data reduction algorithms
require that the relationship between the most important
variables (or the aggregate vectors that represent them) be
orthogonal. PCA is among the most commonly-applied class
discrimination and data decomposition algorithms used in GBM
expression analysis, and it is an example of a linear classifier
requiring that both conditions be satisfied [21]. Here, the former
condition frames the data reduction as a change-of-basis
problem, while the latter allows linear algebra techniques to be
applied to the decomposition in orthonormal space. While these
requirements limit the application of PCA to datasets whose
variables comply with this underlying structure, they can also be
exploited to investigate the relational structure among significant
variables (or, at least, among those with the largest variance) in an
expression data set by comparing the actual to the expected
outcomes. We used PCA to investigate the validity of the
assumptions of linearity and orthogonality for the TCGA GBM
expression data set.
When the underlying data relationships are both linear and
orthogonal, two-dimensional plots of successive principal compo-
nents (PC) should demonstrate that the samples display, on
average, a linear relationship to one another with the regression
line having a y-intercept and slope that approximate zero. Using
the RMA-normalized data set of all 340 GBMs, we performed
PCA and then examined the three, two-dimensional plots of the
first three principal components (PCs 1 vs. 2; 1 vs. 3; and 2 vs. 3;
Figure 14). Examination of the PC 1 vs. 2 plot suggests a linear
correlation of the data but with a regressed slope ,0. This effect
can be observed when both PCs are influenced by one or more
correlated variables and suggests that the first two principal
Figure 11. Data Filtering Analysis. Various combinations of data filtering strategies are applied to the TCGA GBM dataset (as indicated below the
images) and PCA plots colored by survival phenotype (Red=top 20
th percentile; Blue=bottom 20
th percentile; Yellow=intermediate percentiles) are
generated. A summary of the eigenvalue data is presented in tabular form. This analysis suggests that technical variability introduced by genes with
relatively homogeneous or absent expression values is a source of variability but does not appear to be the primary factor impeding accurate
phenotypic classification.
doi:10.1371/journal.pone.0020826.g011
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the PC 1 vs. 3 and PC 2 vs. 3 plots suggest qualitatively that the
samples may be better represented by a nonlinear regression (i.e.
cluster better around an arc than along a straight line). This
artifact, sometimes referred to as a ‘‘horseshoe effect,’’ can be
observed when the relationship between the variables contributing
to the principal components is non-linear [21,58,59]. Although
these observations require further investigation, examination of
the 2-D PC plots raises the possibility of non-linear relationships
between variables and/or non-orthogonal data structure within
the TCGA GBM expression data that may explain some of the
inconsistencies or failures of robust linear classifiers.
Discussion
The Role of Transcriptomic Data in Phenotype Prediction
Laboratory techniques for analyzing the transcriptome, includ-
ing RT-PCR and microarray analysis, have evolved into some of
the most robust and efficient means of collecting large quantities of
molecular data from biological sepcimens. Because assays of the
transcriptome are believed to provide a comprehensive window
through which cellular physiology can be studied, a great deal of
effort and resources have been devoted to large-scale transcrip-
tomic analyses of human disease. It is essential to realize, however,
that these investigations, while comprehensive, are unlikely to be
exhaustive in their ability to predict phenotype. Post-translational
processes also have phenotypic influence, and predictive models
that include this data are likely to have improved accuracy when
compared to transcriptome-only models. Notwithstanding, be-
cause genotype influences phenotype, the transcriptome is likely to
contain valuable information on which predictive models can be
built. The objective of this investigation is to better understand the
potential sources of error in such models and to suggest strategies
for reducing this error. Whether applied to transcriptomic data in
isolation or to such data applied in a more comprehensive
framework, an improved understanding of these error sources can
only improve the predictive ability of molecular models that
incorporate transcriptomic data.
The Noise Problem and its Implications
Large scale molecular datasets, such as those generated by
whole-genome expression analysis, have been heralded by the
translational oncology community as an important step toward
using tumor biology to guide disease diagnosis and therapy.
Because genomic profiles and phenotype are related, it is logical
that molecular signatures associated with specific phenotypes can
be identified retrospectively and used to identify specific
phenotypes with clinical relevance prospectively. Translational
studies performed in the context of this paradigm have succeeded
in both domains, retrospectively identifying differential patterns of
gene expression between tumors from patients with distinct
phenotypes and prospectively using such signatures to classify
accurately novel tumor samples into appropriate phenotypic
categories [8,11,12,13,14,60,61].
Initial enthusiasm inspired by these investigations has tempered,
however, as repeated attempts at molecular subclassification of
various malignancies fail to validate the putative role of genes
identified as relevant by these classification schema and remain
unable to reproduce consistent genomic signatures associated with
similar clinical phenotypes. We believe that these two observations,
Figure 12. Batch Effects Analysis. A–C: Analysis of subsets (A=baseline subset) matched for all technical parameters except for either Hospital of
Origin (B; by TCGA Hospital code, Green=02, Red=08) or TCGA Batch (C; Green=batch 1, Blue=batch 2, Red=Batch 5). Samples do not segregate
by either technical variable, even when all other technical variables are controlled. This suggests that these variables are not major contributors to the
first three principal components. D–E: The ComBAT algorithm was used to correct for batch effects. This changes the distribution along all 3 principal
components (suggesting that batch effects may contribute to these components) but does not improve classification into survival phenotype,
(suggesting that batch effects are not the principal factor confounding the PCA). Note: D–E are colorized by survival phenotype, as in Figure 3A.
doi:10.1371/journal.pone.0020826.g012
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and the inconsistencies in the specific expression patterns on which
such classifications are made, reflect two distinct and equally-
important characteristics of large scale molecular datasets. The
predictive power of classifiers based upon molecular signatures [62]
demonstrates both the wealth of biological information contained in
these datasets and the robustness of the analytic models applied to
the problems of classification based upon this data. This finding
validates the enthusiasm with which these investigations are
undertaken and illuminates their potential utility as clinical tools.
The inconsistencies, however, demonstrate the presence of one or
more sources of noise within the dataset, where noise is defined as
the presence of measured variable values (i.e. gene expression
values) that do not contribute to the intended molecular
classification. Despite thorough investigation, much remains
unknown about the nature and magnitude of the noise, highlighted
by the observed inconsistencies in identifying specific genes and
gene expression signatures useful for classification. While the latter
challenge is surmountable, it risks overshadowing the former
strength unless the sources of such noise can be appropriately
identified, modeled, and suppressed in future translational molec-
ular oncology investigations. This problem spurred the present
investigation.
Data Quantity and Quality Relationships in Translational
Molecular Biology
Strategies employed to reduce noise and improve the accuracy
and precision of genome-based classifiers have focused on
reducing error primarily by increasing the quantity of available
data used in molecular classification investigations. Large,
publically-available repositories of molecular data spanning a
large number of pathologies were developed, including the Gene
Expression Omnibus (GEO) [63,64,65] and The Cancer Genome
Atlas (TCGA) [16]. This approach is consistent with traditional
models of biological and clinical research, where improvements in
power and reduction in error are achieved primarily through
increases in sample size.
Figure 13. Progressive Tumor Population Size Analysis. PCA plots (colored by survival phenotype, Red=top 20
th percentile; Blue=bottom
20
th percentile; Yellow=intermediate percentiles) show no qualitative change in sample distribution as equal subsets are added. 1a–f refers to
individual analyses of the six, equal subsets that were progressively added. Graphical representations of each of these subsets have been omitted in
the interest of space and are, instead, illustrated by a single, representative, graphical description of subset 1a (labeled 1). From this point, the
numbers correspond to the number of subsets present in the analysis. The eigenvalues associated with each subset and with the combined
populations show no significant changes as additional samples are added (tabular, bottom left; graphical, bottom right). PC, principal component.
This analysis demonstrates that the incorporation of additional samples causes some increase in noise, although this does not appear to be a major
factor contributing to the first 3 principal components.
doi:10.1371/journal.pone.0020826.g013
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traditional biological and clinical data sets, however, in the
relationship between the number of samples being studied (n)a n d
the number of variables measured per sample (p). In traditional
datasets,relatively few variablesaretracked acrossaproportionately
greater number of samples (n.p). The inverse is true of modern
molecular datasets, where the number of variables measured per
sample (typically expression levels of individual genes) far exceeds
the number of samples in a given investigation [62] (p&n).T h i s
difference calls into question the validity of traditional models of
error and noise reduction through increasing sample size, and two
types of gross evidence appear to validate these concerns. First,
statistical investigations regarding selection of sample size in
microarray experiments, the details of which are beyond the scope
of this discussion, suggest that large sample sizes may not always be
necessary to draw meaningful biological conclusions
[66,67,68,69,70,71,72]. Second, there is little evidence to suggest
that classifiers derived from more recent investigations using large
numbers of gene expression profiles [11] aremore powerful or more
robust than those generated from investigations performed using
fewer samples [8]. Together, the combination of these theoretical,
statistical, and practical observations suggest that increasing sample
quantity may be neither necessary nor sufficient to reduce noise and
error in analyses of large-scale molecular datasets.
If increasing sample quantity is not necessarily the primary
method for reducing noise and error, then data quality must be
improved. The concept of the ‘‘quality’’ of expression data is
complicated by the fact that the experimental utility of a given
dataset is relative to the biological hypothesis that it is being used
to test. A molecular dataset that may be ideal to answer one
question may contain too much noise to test an alternate
hypothesis. In addition to stressing the importance of appropriate,
initial study design in molecular analyses, this argument suggests
that the concepts of error and noise have a dynamic component
(that is relative to a given investigation) and that error modeling
may need to be individualized [49] for a particular question
addressed using a specific dataset. This reasoning may explain
some of the theoretical underpinnings of the heterogeneity and
variability noted in the core gene expression patterns employed by
modern molecular classifiers.
Another possibility is that cancers, such as GBM, are much
more molecularly diverse than we have previously recognized.
While there may be some common molecular events contributing
to the development and progression of the disease, it may be that
the clinical phenotypes are mediated by large numbers of
interacting genes and that this diversity would require even larger
patient populations to identify the subtle signals that may be
present. Alternately, it may be that a more hypothesis-driven,
pathway-based approach to identifying phenotypically-relevant
subclasses is necessary.
Phenotypic Correlation as the Benchmark
Identification of genotypic tumor subgroups with phenotypic
significance has been used as the benchmark for ‘‘successful’’
molecular tumor subclassification in this investigation. This
strategy has been chosen because it reflects the real-world needs
of translational neurobiologists and neuro-oncologists. These
investigators, who attempt to identify molecular markers in
glioblastoma patients that define discrete diagnostic, prognostic,
or response-to-therapy subpopulations, represent a significant
proportion of the target audience of the TCGA project and are
currently among the most frequent consumers of the gene
expression data housed in this database. While phenotypic
correlations of genomic data are important in nearly all avenues
of research conducted using such databases, we recognize that the
benchmark we have chosen may not be ideally suited to the
specialized needs of some mathematicians, basic scientists, and
systems biologists who may be analyzing the TCGA data with
non-clinical objectives. Notwithstanding, even investigators with
such alternate aims may benefit from the conclusions drawn from
this analysis.
Logic Models and Error in Tumor Classification
Although specific sources of noise and their relative relation-
ships may vary across diverse datasets and for specific clinical
Figure 14. 2-Dimensional Plots of Principal Components 1–3. Two-dimensional plots of the first three principal components of the TCGA
GBM dataset (colored by survival phenotype, Red=top 20
th percentile; Blue=bottom 20
th percentile; Yellow=intermediate percentiles). These plots
may suggest nonlinear and/or nonorthogonal relationships among the features (genes) used for classification. See text for detailed discussion.
doi:10.1371/journal.pone.0020826.g014
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approach the identification of such confounding data. To address
this challenge, we created a logic model we believe is useful for
analyzing many of the potential sources of noise that result in
inconsistent phenotypic classification of malignancies based upon
gene expression data (Figure 1).
Our model is predicated upon two, necessary preconditions;
that distinct phenotypic groups exist within the dataset and that
genomic profiles can be used to predict phenotype. Assuming these
conditions are met, we asked five basic questions, the answers to
which frame a logic model for investigating the potential sources of
noise that impedes reproducible classification into clinically-
relevant phenotypes based upon molecular data. Finally, we apply
this logic model to the TCGA glioblastoma expression dataset to
investigate the potential sources of noise specific to this dataset and
to the challenge of molecular classification of GBM into subgroups
with distinct, clinically-relevant phenotypes. This exercise serves
two purposes. First, it provides a specific analysis of the potential
sources of noise and error that have been confounding attempts at
reproducible subclassification of GBM. Second, it illustrates the
broader concept of design and implementation of a logic model for
error analysis that can be applied, with some individual
modifications, to understand sources of noise and error in similar,
translational investigations.
Logical Analysis of Sources of Noise and Classification
Error in the TCGA GBM Data Set
In the following section we describe the five questions used to
frame our logic model and the results of the 11 individual analyses
performed within the context of the model to investigate the
potential sources of noise and error that result in classification
inaccuracy or variability in the TCGA GBM data set.
a. Preconditions. In order for the TCGA dataset to be
appropriate for the task of molecular subclassification of
GBMs into genomic subgroups with phenotypic significance,
two preconditions must be met. First, there must be multiple,
discrete phenotypes of GBM. This precondition is satisfied by
a wealth of clinical experience demonstrating that patients
with GBM have variable time to progression and recurrence,
survival rates, and response to therapy [1,2,5,8]. Next,
genomic profiles must be useful for predicting tumor
phenotype. This has been demonstrated in multiple investi-
gations where different types of malignancies as well as
different classes of the same general malignancy have been
assigned to the appropriate category based upon genomic
profile, including successful subclassification of GBM
[8,11,12,13,14,60,61]. Additionally, our multiple tumor stratifi-
cation analysis (#1) demonstrated that the TCGA GBM
expression data could be used to successfully separate GBM
from other malignancies, validating this specific precondition
for this particular dataset.
b. Question 1: Do unbiased class discovery methods
accurately identify clinical phenotypes of GBM
based upon analysis of the TCGA GBM expression
data? The unsupervised classification and clinical parameters analysis
(#2) addressed this question by applying several unsupervised
classification algorithms to the TCGA GBM expression data.
No algorithm was able to accurately stratify the tumors by
subclass in any of 8 clinically-relevant, phenotypic categories.
These results demonstrate that gene expression-based analysis
fails to classify patients into appropriate clinical subclasses,
suggesting that some type(s) of noise is present within the data
and confound attempts at molecular classification. This
observation differs from some of those previously reported
independently by several groups, who found that phenotyp-
ically-relevant (survival) GBM subgroups could be identified
based upon gene expression data [8,12,13,15]. However,
these previous studies were generally conducted within a
single center and were performed using smaller and more
homogeneous experimental populations. Tissue for these
studies may have been more carefully selected, and clinical
characteristics of patients whose tissues were analyzed may
have been more rigorously reviewed to verify satisfaction of
multiple inclusion criteria. All of these factors reduce analytic
noise by limiting some of the variability within the dataset,
and it is not surprising that accurate phenotypic classification
is more challenging in the more heterogeneous, TCGA
dataset.
c. Question 2: Do clinical and phenotypic differences
exist within the data set? One potential reason for failure
of the molecular classification strategies that must be
addressed at the outset would be the absence of genomic or
phenotypic differences within the TCGA GBM dataset.
Phenotypic variability among GBMs has been well described
in general (see preconditions) [1,2,5,8], and review of the clinical
data associated with this particular dataset revealed the
expected variability among each of the 8 categories analyzed
in analysis #2 (data not shown), indicating that various
clinical phenotypes are also present within the dataset.
Genomic variability is also well described among GBMs
[8,11,12,13,14,60,61], and biological analysis of the unique
expression signature of the outlier group identified in the
biologic analysis of the outlier group (#3) exercise demonstrates
plausible biological variability among samples in this specific
data set. Accordingly, we conclude that genomic and
phenotypic differences do exist in the TCGA GBM dataset.
d. Question 3: Why are underlying differences among
the expression data not identified by the unsuper-
vised analysis? Several unsupervised, linear classifiers and
dimensional reduction strategies failed to classify the TCGA
GBM data into phenotypically-significant groups. The
eigenvalue data analysis (#4) suggests that these classifiers (for
which we use PCA as a prototype) fail to capture a large
percentage (.70%) of the variability inherent in the dataset.
In general, the types of linear algorithms used commonly in
molecular GBM subclassification (and therefore used in this
exercise) are unsuccessful when one of two, necessary criteria
are not satisfied; either (1) the mean and standard deviation do
not accurately and sufficiently represent the dataset, or (2) the
relationships between genomic profile and clinically-relevant
phenotype are either non-linear or non-orthogonal. Individ-
ually, these criteria form the basis of questions four and five.
e. Question 4: Do the mean and standard deviation
accurately and sufficiently represent the dataset? In
this analysis, the mean and standard deviation may fail to
appropriately represent the dataset in one of two circum-
stances. First, they insufficiently describe the dataset when the
values of the variables serving as the basis of classification do
not follow a Gaussian distribution [36]. The expression data
distribution analysis (#5) demonstrates that the underlying data
distribution in the TCGA GBM data is not purely Gaussian,
with statistically-significant skew and kurtosis apparent in both
the composite expression matrix and among the expression
levels of the individual variables (genes). The ultimate
significance of this with regard to classification requires
further, dedicated investigation [36,38], but it provides one
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to this dataset.
A second circumstance where mean and standard deviation
fail to appropriately represent the dataset is when features
with the largest variance are not the primary contributors to
the clinically-relevant phenotypes. Stated differently, linear
classifiers fail when the signal-to-noise ratio of the dataset is
low. In this context, the term noise is defined as the presence of
measured variable values (i.e. gene expression values) that do
not contribute to the intended molecular classification, and, as
discussed earlier, is relative to the clinical question(s) being
asked. In molecular classification experiments using gene
expression data, both technical and biological noise can
impede accurate classification.
1) Technical noise is present when procedural artifacts are
reflected in the values of the variables. We investigated
potential sources of technical noise, including those associated
with sample preparation (#7), the array platform (#7), the
inclusion of low-variance or incomplete expression data (#8),
batch effects (#9), and sample size (#10). We demonstrated
the presence of technical noise associated with all of these
domains within the TCGA GBM dataset, although no single
domain appeared to be the primary contributor to inaccurate
phenotypic subclassification. Investigation of the relative
magnitude of the individual contributions to the overall error
and the aggregate effects of these sources of technical noise on
the overall classification accuracy require detailed modeling
strategies that are only beginning to be developed and that
are beyond the scope of this analysis. Notwithstanding, our
analysis demonstrates the importance of ongoing research
into such modeling and highlights technical noise as one,
important area for additional investigation.
2) Biological noise [56,73] is present when the values of the
variables (gene expression values) accurately reflect underly-
ing biology but still confound subclassification into clinically-
significant subgroups. This can occur in one of three ways: (1)
the expression values reflect underlying biology that does not
contribute to clinically-relevant phenotypes, (2) the expression
values reflect biological differences that make proportionally
low magnitude contributions to clinically-relevant pheno-
types, or (3) the expression values reflect biology that does
contribute to clinically-relevant phenotypes, but these
phenotypes either are not included in or are not detected
by our analytic model. Specific analysis of the relative
magnitude of the effects from each of these categories
requires not only complex modeling that is beyond the scope
of our investigation, but also some a priori knowledge of the
underlying systems biology of the tumor that may not be
known. These, too, must be areas of active research if the
sources of error in large-scale, molecular datasets are to be
accurately described.
f. Question 5: Are the relationships between features
(genes) and clinically-relevant phenotype linear and
orthogonal? Linear classifiers and dimensional reduction
algorithms, by definition, are designed to classify based
upon linear combinations of feature values associated with
the members of the dataset [36]. Additionally, many
common data reduction algorithms (including PCA) require
orthogonal relationships between features (or their mathe-
matical aggregates) so that linear algebra strategies can be
used to facilitate data reduction [21]. Without a detailed
understanding of the systems biology of the tumor being
studied, it is impossible to knowf o rc e r t a i nw h e t h e ra n yo r
all relevant features are related in a linear (or orthogonal)
fashion. A basic understanding of the complex principles
underlying gene regulation, signal transduction, and
malignant transformation, however, provide no particular
basis for the assumptions of linearity or orthogonality and,
in fact, may logically favor a non-linear and non-orthogonal
relationship among genes. These relationships may be
present across the entire expression spectrum of a given
gene or above or below a specific expression threshold.
Although nonlinear relationships are difficult to demon-
strate definitively in incompletely-characterized biological
systems, we exploited knowledge of the mathematics
underlying principal component analysis and the expected
relationships between the identified PCs [21,58,59] to
provide qualitative evidence suggesting underlying non-
linear and/or non-orthogonal relationships among features
(#11). These findings argue in favor of application of
classifiers that do not assume linearity or orthogonality (e.g.,
kernel PCA), strategies which are now being described by
array statisticians [74] but have yet to see broad application
by the translational research community. Including nonlin-
ear models in future analyses of large-volume, molecular
datasets (including the TCGA data) may be a critical step to
improving the accuracy of class discovery and prospective,
molecular classification.
Limitations
The investigation that we have performed focuses on the
TCGA gene expression data and is therefore subject to two,
general limitations inherent to this dataset. First, the TCGA
expression data that we have analyzed reflects only genome-level
changes in tumor biology. While gene expression is believed to
correlate with phenotype, protein-level data may also be a
valuable resource for molecular classification of glioblastoma
[75]. Second, the TCGA gene expression data has been collected
from surgical tumor specimens that necessarily contain a mixture
of neoplastic and non-neoplastic cells. While this may be more
significant for investigations of tumor biology than for those
focusing on molecular tumor classification [8,55], this consider-
ation must be appreciated by investigators working with this
dataset.
We also recognize that the logic model that we have described
and the analysis of the TCGA GBM data that we have performed
have some limitations. First, we recognize that our model may not
encompass every potential source for noise or error in this
particular dataset and that generalization of our model to other
datasets and/or to investigations of alternate hypotheses may
require inclusion or exclusion of additional confounding factors.
Nonetheless, we believe that our model provides a logical
framework for analyzing error that is readily expandable should
modification of the specific sources of noise or error become
necessary or should alternate, potential sources of error be
identified. Similarly, while our logic model may be useful for
prospectively exploring and limiting potential sources of error
when designing novel studies, we would not support the conclusion
that such a strategy necessarily assures generation of ‘‘high-
quality’’ data and caution that such a conclusion exemplifies the
logical burden-of-proof fallacy. Finally, while our model has
allowed us to identify several targeted areas for future efforts to
improve the quality of the TCGA GBM data, we recognize that
research in additional domains may also be necessary to improve
the translational potential of this dataset.
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We have constructed a logic model that facilitates a compre-
hensive analysis of potential sources of noise and error that may be
responsible for some portion of the inconsistencies and lack of
reproducibility observed in recent attempts to use constituent data
from the TCGA GBM expression dataset to classify GBMs into
clinically-relevant phenotypes. We believe that this model is a
useful tool to conduct such analyses and can be readily adapted as
new information regarding error and noise becomes available, and
we believe it may be readily generalized to the systematic study of
error in other translational domains.
Based upon our application of this logic model to the TCGA
GBM expression data, we make seven conclusions regarding the
potential sources of inconsistencies and error among molecular
classifiers based upon the expression data comprising this dataset.
1) Because there is evidence that supports the existence of
genomic and phenotypic variability within the dataset, the
failure to discover genomic associations correlated with
clinically-relevant phenotypes may reflect a classification
failure by the common, linear classification algorithms
commonly employed in this and in most other analyses of
gene expression data.
2) The mean and standard deviation do not accurately and
sufficiently describe either the overall expression matrix or
the expression values of the individual genes contained
therein.
3) Neither the distribution of the overall expression matrix nor
the expression distributions of the genes or samples conform
to a pure Gaussian distribution.
4) Technical noise, and likely biological noise as well, limit the
signal-to-noise ratio of this dataset with respect to molecular
tumor classification into phenotypically-relevant subsets.
5) Technical noise is present within the data, but none of the
measured sources appear to individually represent the
primary source of classification-limiting noise.
6) Biological noise is assumed to be present based upon the
logic model but cannot be accurately measured using
current error modeling strategies.
7) There is a suggestion of non-linear and/or non-orthogonal
relationships among genes affecting clinically-relevant GBM
phenotypes in this dataset.
Finally, the results of our analysis suggest that targeted research
in four, specific areas may further efforts to improve classification
accuracy and reproducibility by reducing noise in the TCGA
dataset. These areas include: (1) additional research regarding the
underlying distribution of the dataset and the implications of this
distribution for classification algorithms, (2) expanded develop-
ment and application of non-linear and/or non-orthogonal
classifiers to this data, (3) efforts to improve modeling of technical
noise, (4) and expanded efforts to model biological noise in the
context of improved understanding of the systems biology of
GBMs.
Methods
Logic Model
A logic model for directing data analysis was constructed and is
depicted in Figure 1. This model was used to identify and to place
in context five, fundamental questions that served as the guide for
data analysis (see discussion). Based on logic model structure,
eleven mathematical analyses (indicated numerically on Figure 1
and described below) were then designed to answer these five
questions. Publically-available GBM gene expression data, with
corresponding clinical and technical data, was prepared as
described and was then used as the data source for these analyses.
Gene Expression Datasets
The primary GBM gene expression dataset for this project was
compiled from publically-available, TCGA GBM data [16].
AffymetrixH .cel files for all 340 GBM samples profiled using the
AffymetrixH HT-HG-U133A chip available through TCGA as of
1 October 2009 were downloaded and were included in
subsequent analyses. To facilitate biological comparisons from
the analyses performed using this data set, four .cel files from
normal brain tissue profiled on the same AffymetrixH platform
were downloaded from GEO [63,64,65]. A second dataset was
then constructed, including all 340 GBMs plus the four normal
brain samples, which served as controls in analyses involving
interpretation of tumor biology. Finally, a multiple-tumor dataset
was compiled for use in the multiple tumor classification
investigation. This dataset comprised all 340 GBMs plus an
additional twenty (20) renal cell carcinomas (RCC) and four (4)
hepatocellular carcinomas (HCC). The latter 24 samples were also
profiled using the AffymetrixH HT-HG-U133A chip, and the.cel
files were downloaded from GEO.
Expression Data Preparation
Three datasets were prepared and were used in all subsequent
analyses. The first was composed of all 340 GBM samples, the
second comprised all 340 GBM samples plus the four normal
brain controls, and the third consisted of all 340 GBM samples
plus the 24 non-GBM tumors. Each dataset was normalized using
the Robust Multichip Average (RMA) [22,23,76] with background
adjustment, quantile normalization, and PLM summarization.
When indicated, an alternate normalization strategy using the
AffymetrixH MAS5 method [54] was utilized. All normalized
expression values were log2 converted.
For the dataset containing normal brain tissue, and average
expression value for each gene across the four control samples was
computed. The expression variance among each gene was
computed for the controls, and the most variable 10%,
representing the genes with the least consistent expression in the
control dataset, were removed from downstream analyses (as
previously described). The log2 (tumor/normal) expression value
for each of the remaining genes was computed in each of the 340
samples, and this dataset was used in subsequent analyses
involving biological interpretation of data. This method of data
preparation has been previously described in GBM expression
analyses.
A one-sided Significance Analysis for Microarray (SAM) [27,28]
algorithm with a false discovery rate (FDR) set to zero was applied
to each of the three datasets to exclude genes whose expression
values were not statistically significant from baseline (zero or
control). These genes do not meaningfully contribute to classifi-
cation and can impede downstream analyses. These three datasets
were used, as indicated, in the eleven analyses performed in this
investigation.
Clinical and Technical Data
Access to restricted clinical data was granted through the
standard TCGA data access protocol. Clinical data (when
available), including survival, time to progression, time to
recurrence, Karnofsky performance status (KPS), sex, adjuvant
chemotherapy, adjuvant radiotherapy, and presence of necrosis
and endothelial proliferation in histologic sections, was merged
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Similarly, data regarding the technical processing and specimen
quality, including prior treatment, relative abundance of tumor
cells, tissue block size, hospital of origin, TCGA batch number,
extracted RNA concentration, OD260/280, 28S/18S, and RNA
integrity number (RIN), was similarly collected and merged for
analyses involving these parameters.
Data Analysis
Microsoft Excel was used for data preparation. The TM4
software package [77,78] was used to analyze gene expression
data. Analyses performed using TM4 include hierarchical
clustering and support (HCS, bootstrapping with 20 iterations)
[19], k-means clustering and support [25] (KMS, 10 iterations
with 80% clustering threshold), k-nearest neighbor classification
(KNNC) [26], and principal component analysis [20,21] (PCA).
Differences were considered statistically-significant at p,0.05,
unless otherwise indicated.
PCA as a Prototypical Linear Classifier
Initial analyses used multiple classification algorithms, including
HCS, KMS, and PCA to verify that all of these linear methods
resulted in qualitatively-equivalent results in class discrimination
investigations. Subsequently, PCA was used as a prototypical
discriminator because of the robust nature of the algorithm and
the logical, graphical representation of its class discrimination.
Supporting Information
Figure S1 Logic Model for Analyzing Variability in the
TCGA GBM Dataset, Unannotated. Logic model applied for
data analysis, without annotations (see Figure 1 for annotated
version and for detailed explanation). Supplied for reference
purposes.
(TIF)
Table S1 Genes Differentially Expressed between the
Outlier Cluster and the Remaining GBMs. Relative fold
change values computed using 2-sided significance analysis for
microarrays (SAM) with false discovery rate (FDR)=0. Statistical
significance of categorical annotations computed using the EASE
score (adjusted Fisher Exact Test). 1A: Overexpressed in the
outlier group relative to the remainder. 1B: Underexpressed in the
outlier group relative to the remainder. 1C: EASE analysis of
overrepresented categories in the overexpressed genes. 1D: EASE
analysis of overrepresented categories in the overexpressed genes.
1E: Overlap between differentially expressed genes and categories
in the outlier group and those identified in a previously-described
GBM expression fingerprint with putative relationship to the
survival phenotype [8].
(XLS)
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